Mirae Asset Global Investments Co., Ltd. Protagonist Therapeutics, Inc Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,394 shares of PTGX stock, worth $182,350. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,394
Previous 2,054
16.55%
Holding current value
$182,350
Previous $99,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PTGX
# of Institutions
295Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$470 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$439 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$438 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$332 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$247 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.74B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...